Evidence map›Paper›PMID 27980565›Full record

ArticleIranian journal of pharmaceutical research : IJPR2016

Synthesis and Acetylcholinesterase Inhibitory Evaluation of 4-(1,3-Dioxoisoindolin-2-yl)-

Ahmad Mohammadi-Farani, Samira Soltani Darbandi, Alireza Aliabadi

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. A Series of Novel 1-Molecules (Basel, Switzerland) · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ahmad Mohammadi-FaraniPharmaceuticalSciencesResearchCenter, FacultyofPharmacy, KermanshahUniversityofMedicalSciences, Kermanshah, Iran. ; DepartmentofPharmacology, ToxicologyandMedicalServices, FacultyofPharmacy, KermanshahUniversityofMedicalSciences, Kermanshah, Iran.
Samira Soltani Darbandi.StudentsResearchCommittee, KermanshahUniversityofMedicalSciences, Kermanshah, Iran.; DepartmentofMedicinalChemistry, FacultyofPharmacy, KermanshahUniversityofMedicalSciences, Kermanshah, Iran.
Alireza AliabadiPharmaceuticalSciencesResearchCenter, FacultyofPharmacy, KermanshahUniversityofMedicalSciences, Kermanshah, Iran. ; DepartmentofMedicinalChemistry, FacultyofPharmacy, KermanshahUniversityofMedicalSciences, Kermanshah, Iran.
Kermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer᾽s disease is characterized by cognitive deficits, impaired long-term potentiation of learning and memory. A progressive reduction in cholinergic neurons in some areas of the brain such as cortex and hippocampus is related to the deficits in memory and cognitive function in Alzheimer's disease (AD). In the current project a new series of phthalimide derivatives were synthesized. Phthalic anhydride was reacted with 4-aminobenzoic acid in the presence of triethylamine under reflux condition. Then, the obtained acidic derivative was utilized for preparation of final compounds via an amidation reaction through a carbodiimde coupling reaction. Anti-acetylcholinesterase activity of synthesized derivatives was assessed by Ellman᾽s test. Compound 4g in this series exhibited the highest inhibitory potency (IC

Indexed as

AcetylcholinesteraseAlzheimerPhthalimideSynthesis

Identifiers

PMID27980565
PMCPMC5149017
OpenAlexW2501625485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.